- Home
- HBB vs ENGN Comparison
HBB vs ENGN Comparison
Compare HBB & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBB
- ENGN
- Stock Information
- Founded
- HBB 1904
- ENGN 1999
- Country
- HBB United States
- ENGN Canada
- Employees
- HBB N/A
- ENGN N/A
- Industry
- HBB Home Furnishings
- ENGN
- Sector
- HBB Consumer Discretionary
- ENGN
- Exchange
- HBB Nasdaq
- ENGN Nasdaq
- Market Cap
- HBB 292.6M
- ENGN 317.6M
- IPO Year
- HBB 2017
- ENGN N/A
- Fundamental
- Price
- HBB $17.09
- ENGN $6.14
- Analyst Decision
- HBB
- ENGN Strong Buy
- Analyst Count
- HBB 0
- ENGN 9
- Target Price
- HBB N/A
- ENGN $29.78
- AVG Volume (30 Days)
- HBB 52.5K
- ENGN 214.2K
- Earning Date
- HBB 10-30-2024
- ENGN 12-19-2024
- Dividend Yield
- HBB 2.68%
- ENGN N/A
- EPS Growth
- HBB 107.04
- ENGN N/A
- EPS
- HBB 1.88
- ENGN N/A
- Revenue
- HBB $647,834,000.00
- ENGN N/A
- Revenue This Year
- HBB $4.60
- ENGN N/A
- Revenue Next Year
- HBB N/A
- ENGN N/A
- P/E Ratio
- HBB $8.63
- ENGN N/A
- Revenue Growth
- HBB 5.30
- ENGN N/A
- 52 Week Low
- HBB $14.34
- ENGN $4.42
- 52 Week High
- HBB $31.78
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- HBB 34.89
- ENGN 34.84
- Support Level
- HBB $15.90
- ENGN $5.60
- Resistance Level
- HBB $17.07
- ENGN $6.54
- Average True Range (ATR)
- HBB 0.89
- ENGN 0.70
- MACD
- HBB 0.11
- ENGN -0.11
- Stochastic Oscillator
- HBB 30.13
- ENGN 17.70
About HBB Hamilton Beach Brands Holding Company
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.